Palvella Therapeutics

Yahoo Finance • 10 days ago

Palvella Therapeutics price target raised to $200 from $120 at Oppenheimer

Oppenheimer raised the firm’s price target on Palvella Therapeutics (PVLA) to $200 from $120 and keeps an Outperform rating on the shares after the company reported the Phase 2 TOIVA readout for Qtorin rapamycin in cutaneous venous malform... Full story

Yahoo Finance • 12 days ago

Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approved Therapies

73% of trial participants (11/15 participants) improved on the Overall Cutaneous Venous Malformations Investigator Global Assessment (Overall cVM-IGA) at Week 12; 67% of trial participants (10/15 participants) rated as “Much Improved” (+2)... Full story

Yahoo Finance • 2 months ago

Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference

WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients... Full story

Yahoo Finance • 2 months ago

Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies

DSAP is a premalignant, progressive disease characterized by numerous expanding lesions which significantly impact quality-of-life; no FDA-approved therapies exist for the estimated more than 50,000 diagnosed U.S. patients QTORIN™ pitavas... Full story

Yahoo Finance • 2 months ago

U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics’ Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

Second year proceeds granted following FDA review of annual performance progress report on Phase 3 SELVA single-arm, baseline-controlled trial; up to $2.6 million in non-dilutive funding anticipated over the grant period Top-line data fro... Full story

Yahoo Finance • 3 months ago

These Were the Russell 2000 Stocks That Dominated In Q3 2025

The small cap-focused Russell 2000 index has spent years lagging behind the larger S&P 500 and Nasdaq 100 indexes, but in third-quarter 2025 it took a big leap back to parity with large caps. Thanks to interest-rate-cut bets and optimism... Full story

Yahoo Finance • 3 months ago

Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies

Clinically significant angiokeratomas are characterized by lymphatic-derived skin lesions that can persistently bleed and significantly impact quality-of-life; no FDA-approved therapies exist for the estimated more than 50,000 diagnosed U.... Full story

Yahoo Finance • 3 months ago

Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy

Recent advances in understanding venous malformation disease pathogenesis highlight the PI3K/AKT/mTOR pathway as a key driver of disease proliferation, spurring real-world off-label use of systemic rapamycin (sirolimus) Publication includ... Full story

Yahoo Finance • 3 months ago

Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations

Phase 2 TOIVA trial successfully met recruitment target, enrolling 16 subjects at leading vascular anomaly centers; top-line data expected in mid-December 2025 Venous malformations are the most common type of vascular malformation, with s... Full story

Yahoo Finance • 4 months ago

Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer

Co-Founder and former Chief Technical Officer of Arcutis Biotherapeutics brings extensive topical product development experience, including track record of translating science into commercially available therapies Dr. Osborne to guide exp... Full story

Yahoo Finance • 4 months ago

Is Bio-Rad Laboratories (BIO) Entering a Period of More Sustained Recovery?

Prosper Stars & Stripes, a long/short equity fund, recently released its second quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund underperformed and generated a net return of +9.6% compared to a total retu... Full story

Yahoo Finance • 4 months ago

Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences

WAYNE, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from se... Full story

Yahoo Finance • 4 months ago

Palvella Therapeutics Inc (NASDAQ:PVLA) Reports Wider Q2 2025 Loss, Stock Drops 13% Despite Clinical Progress

Palvella Therapeutics Inc (NASDAQ:PVLA [https://www.chartmill.com/stock/quote/PVLA]) reported its second-quarter 2025 financial results, posting a net loss of $0.86 per share, missing analyst estimates of a $0.76 loss. Revenue for the quar... Full story

Yahoo Finance • 4 months ago

Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations completed enrollment, exceeding enrollment target by over 25%; top-line results on track for the first quarter... Full story

Yahoo Finance • 5 months ago

Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

WAYNE, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from se... Full story

Yahoo Finance • 6 months ago

Palvella Therapeutics Completes Enrollment for Pivotal Phase 3 Trial of QTORIN Rapamycin

Palvella Therapeutics Inc. (NASDAQ:PVLA) is one of the best-performing NASDAQ stocks according to analysts. On June 23, Palvella Therapeutics announced the successful completion of enrollment for its Phase 3 SELVA trial. The trial is evalu... Full story

Yahoo Finance • 6 months ago

Palvella Therapeutics to join Russell 3000 and Russell 2000 Indexes

Palvella Therapeutics (NASDAQ:PVLA [https://seekingalpha.com/symbol/PVLA]) Monday  said [https://seekingalpha.com/pr/20151515-palvella-therapeutics-added-to-russell-3000-and-russell-2000-indexes]that it has been added to the broad-market R... Full story

Yahoo Finance • 6 months ago

Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes

WAYNE, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from se... Full story

Yahoo Finance • 6 months ago

Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%

Enrollment of 51 subjects highlights significant unmet need in this serious, lifelong genetic disease which currently has no FDA-approved therapies Top-line data expected in the first quarter of 2026 WAYNE, Pa., June 23, 2025 (GLOBE NE... Full story

Yahoo Finance • 6 months ago

Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1“20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors

New intellectual property builds on Palvella’s multi-layered exclusivity strategy Patent term expected through at least 2038 WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinica... Full story